JP2024518178A5 - - Google Patents
Info
- Publication number
- JP2024518178A5 JP2024518178A5 JP2023570358A JP2023570358A JP2024518178A5 JP 2024518178 A5 JP2024518178 A5 JP 2024518178A5 JP 2023570358 A JP2023570358 A JP 2023570358A JP 2023570358 A JP2023570358 A JP 2023570358A JP 2024518178 A5 JP2024518178 A5 JP 2024518178A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acids
- polypeptide
- seq
- acid sequence
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163188816P | 2021-05-14 | 2021-05-14 | |
| US63/188,816 | 2021-05-14 | ||
| PCT/US2022/072302 WO2022241465A1 (en) | 2021-05-14 | 2022-05-13 | Compositions of growth factor for the treatment of eye disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024518178A JP2024518178A (ja) | 2024-04-25 |
| JP2024518178A5 true JP2024518178A5 (enExample) | 2025-05-19 |
Family
ID=81756753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023570358A Pending JP2024518178A (ja) | 2021-05-14 | 2022-05-13 | 眼疾患の治療のための増殖因子の組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230022990A1 (enExample) |
| EP (2) | EP4574211A3 (enExample) |
| JP (1) | JP2024518178A (enExample) |
| KR (1) | KR20240035394A (enExample) |
| CN (1) | CN117677394A (enExample) |
| AU (1) | AU2022272740A1 (enExample) |
| BR (1) | BR112023022474A2 (enExample) |
| CA (1) | CA3218000A1 (enExample) |
| IL (1) | IL308496A (enExample) |
| MX (1) | MX2023012782A (enExample) |
| TW (1) | TW202310868A (enExample) |
| WO (1) | WO2022241465A1 (enExample) |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| DE3169595D1 (en) | 1980-11-10 | 1985-05-02 | Gersonde Klaus | Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| ATE159858T1 (de) | 1983-09-26 | 1997-11-15 | Ehrenfeld Udo | Mittel und erzeugnis für die diagnose und therapie von tumoren sowie zur behandlung von schwächen der zelligen und humoralen immunabwehr |
| US4615885A (en) | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
| US5510329A (en) * | 1988-04-26 | 1996-04-23 | Ramot University For Applied Research And Industrial Development Ltd. | Preparations for the treatment of eyes |
| NZ232813A (en) | 1989-03-10 | 1992-08-26 | Snow Brand Milk Products Co Ltd | Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons |
| JP3927248B2 (ja) | 1995-07-11 | 2007-06-06 | 第一製薬株式会社 | Ｈｇｆ凍結乾燥製剤 |
| JP2000344680A (ja) * | 1999-05-31 | 2000-12-12 | Mitsubishi Chemicals Corp | Ｈｇｆ含有医薬組成物 |
| ATE359809T1 (de) | 1999-05-31 | 2007-05-15 | Mitsubishi Chem Corp | Gefriergetrocknete hgf-präparationen |
| AU2003272536A1 (en) * | 2002-09-18 | 2004-04-08 | Emiliano Ghinelli | Use of a human amniotic membrane composition for prophylaxis and treatment of diseases and conditions of the eye and skin |
| EP2014676B1 (en) * | 2006-04-20 | 2012-03-07 | Kringle Pharma Inc. | Hgf precursor protein mutant and activated form thereof |
| WO2008102452A1 (ja) | 2007-02-22 | 2008-08-28 | Kringle Pharma Inc. | Ｈｇｆ製剤 |
| US8895508B2 (en) * | 2009-07-24 | 2014-11-25 | Yasuhiki Tabata | Methods for corneal endothelial proliferation using bFGF sustained-release gelatin hydrogel particles |
| CA2947396C (en) * | 2014-04-28 | 2021-10-19 | Eisai R&D Management Co., Ltd. | Lyophilized formulation of hgf |
| WO2016039163A1 (ja) | 2014-09-10 | 2016-03-17 | クリングルファーマ株式会社 | 神経疾患の治療に適したｈｇｆ製剤 |
| US10449234B2 (en) | 2015-09-11 | 2019-10-22 | The Schepens Eye Research Institute, Inc. | Compositions and methods for prevention and treatment of corneal haze and scarring |
| DK3619324T3 (da) * | 2017-05-05 | 2025-09-22 | Trefoil Therapeutics Inc | Rekombinante modificerede fibroblast-vækstfaktorer og terapeutiske anvendelser heraf |
| JP2023532046A (ja) * | 2020-06-26 | 2023-07-26 | トレフォイル セラピューティクス，インク． | 組換え修飾線維芽細胞増殖因子およびそれを使用した治療 |
-
2022
- 2022-05-13 IL IL308496A patent/IL308496A/en unknown
- 2022-05-13 BR BR112023022474A patent/BR112023022474A2/pt unknown
- 2022-05-13 EP EP25163012.5A patent/EP4574211A3/en active Pending
- 2022-05-13 KR KR1020237042977A patent/KR20240035394A/ko active Pending
- 2022-05-13 MX MX2023012782A patent/MX2023012782A/es unknown
- 2022-05-13 CN CN202280047869.4A patent/CN117677394A/zh active Pending
- 2022-05-13 TW TW111118098A patent/TW202310868A/zh unknown
- 2022-05-13 US US17/743,488 patent/US20230022990A1/en active Pending
- 2022-05-13 CA CA3218000A patent/CA3218000A1/en active Pending
- 2022-05-13 EP EP22725696.3A patent/EP4337243A1/en active Pending
- 2022-05-13 JP JP2023570358A patent/JP2024518178A/ja active Pending
- 2022-05-13 WO PCT/US2022/072302 patent/WO2022241465A1/en not_active Ceased
- 2022-05-13 AU AU2022272740A patent/AU2022272740A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS61103836A (ja) | フイブロネクチン製剤 | |
| RU2510279C2 (ru) | Новые защитные композиции для рекомбинантного фактора viii | |
| JP2025148550A5 (enExample) | ||
| CN101084008B (zh) | 角质形成细胞生长因子的治疗制剂 | |
| KR100700869B1 (ko) | Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물 | |
| WO1997002832A1 (fr) | Preparations lyophilisees de hgf | |
| JPH10212241A (ja) | Ｂｄｎｆを安定に含有する製剤 | |
| FI4228676T3 (fi) | Koostumuksia, jotka sopivat vastasyntyneillä käytettäviksi | |
| JP6996713B2 (ja) | チモシンベータ４を含む眼科用製剤の製造方法 | |
| JPWO1999044630A1 (ja) | 蛋白非添加製剤 | |
| US9060977B2 (en) | Heparin binding epidermal growth factor (HB-EGF) for use in methods of treating and preventing intestinal injury related to hemorrhagic shock and resuscitation | |
| JP2015221835A (ja) | α‐１プロテイナーゼインヒビターのための組成物、方法およびキット | |
| CN111386337A (zh) | 包含胸腺素β4或其衍生物作为活性成分的用于促进杯状细胞增殖或粘蛋白分泌的组合物 | |
| JP4732896B2 (ja) | Ｇ−ｃｓｆと血管新生作用を有する因子の併用 | |
| US20220265782A1 (en) | Stabilizing therapeutic proteins with piperazin- or morpholine-containing zwitterionic buffering substances | |
| KR100330540B1 (ko) | 안티트롬빈-iii액상제제및그안정화방법 | |
| JPH02193931A (ja) | 角膜疾患治療用点眼剤 | |
| JP2025502349A (ja) | Ｉｇｆ－１／ｉｇｆｂｐの酸化を低減するための組成物および方法 | |
| JP3820607B2 (ja) | アンチトロンビン−ｉｉｉの液状製剤およびその保存安定化方法 | |
| JP3859710B2 (ja) | 虚血性疾患の予防及び／又は治療剤 | |
| JP2024506718A5 (enExample) | ||
| KR100537260B1 (ko) | 인간 성장 호르몬의 안정화된 액상 제제용 조성물 | |
| JPWO1996032960A1 (ja) | 虚血性疾患の予防及び／又は治療剤 | |
| EA026073B1 (ru) | Состав бычьего гранулоцитарного колониестимулирующего фактора и способ лечения с его использованием | |
| JP2000344680A (ja) | Ｈｇｆ含有医薬組成物 |